Synthesis and antiviral activities of novel N-alkoxy-arylsulfonamide-based HIV protease inhibitors.
A series of novel N-alkoxy-arylsulfonamide HIV protease inhibitors with low picomolar enzyme activity and single digit nanomolar antiviral activity is disclosed.
GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, NC 27709, USA. ron.g.sherrill@gsk.com
Ronald G
RG
Sherrill
Eric S
ES
Furfine
Richard J
RJ
Hazen
John F
JF
Miller
David J
DJ
Reynolds
Douglas M
DM
Sammond
Andrew
A
Spaltenstein
Pat
P
Wheelan
Lois L
LL
Wright
D001555:Benzene Derivatives / Q000737:chemistry; D015195:Drug Design; D024921:Drug Resistance, Multiple, Viral; D016333:HIV Protease / Q000187:drug effects / Q000378:metabolism*; D017320:HIV Protease Inhibitors / Q000138:chemical synthesis* / Q000494:pharmacology*; D006801:Humans; D013329:Structure-Activity Relationship; D013449:Sulfonamides / Q000138:chemical synthesis* / Q000494:pharmacology; D014779:Virus Replication / Q000187:drug effects
D001555:Benzene Derivatives; D017320:HIV Protease Inhibitors; D013449:Sulfonamides; D016333:HIV Protease